VVOS
Vivos Therapeutics, Inc. (VVOS) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
VVOS shows limited disclosed environmental intensity in the provided metrics, but the absence of emissions, energy, and waste data leaves its peer-relative footprint difficult to verify.
Zero reported R&D intensity suggests a lighter direct resource burden than peers with manufacturing or heavy-process exposure, though this is not evidence of superior environmental management.
The company’s disclosed capital profile does not indicate material environmental liabilities, but peer comparison remains constrained because no climate or resource-use metrics are provided.
Overall environmental positioning appears broadly neutral versus peers, with limited evidence of structural disadvantage but also insufficient disclosure to support a stronger score.
Social
VVOS’s low stock-based compensation to revenue suggests less dilution-linked employee incentive pressure than peers with heavier equity compensation, supporting a more balanced labor-cost structure.
The provided metrics do not include workforce safety, turnover, or diversity data, so social performance cannot be confirmed as stronger than peers on core human-capital indicators.
A gross profit margin near 60% can support internal capacity for employee investment, but this is only an indirect social signal and not a direct peer advantage.
Overall social positioning is modestly better than peers on compensation discipline, yet the lack of disclosed workforce metrics limits confidence in a stronger relative assessment.
Governance
VVOS’s stock-based compensation to revenue is low, which can indicate tighter governance over dilution than peers with more aggressive equity issuance.
The negative debt-to-equity ratio and net debt-to-EBITDA figures suggest an atypical capital structure, but the provided data do not clarify whether this reflects governance strength or accounting effects.
No filing-based information on board independence, audit quality, or shareholder rights is provided, limiting assessment of governance relative to peers.
Overall governance appears average to slightly better than peers on capital discipline, but disclosure gaps prevent a stronger conclusion.
Overall Score
VVOS appears broadly middle-of-pack versus peers, with modest support from compensation discipline but insufficient ESG disclosure to establish a stronger relative position.
Score Driver: Limited ESG Disclosure Across Environmental And Social Metrics Constrains Evidence Of A Clear Peer Advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vivos Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
